Monitoring Anti-TNF alpha Biotherapy to Customise Patient Treatment
30 Oct 2013

A new range of Theranostic Assays is now available in the UK, exclusively from Alpha Laboratories, that will help clinicians to tailor individual Anti-TNF alpha treatments. Such testing and customisation of drug regimes aids the most effective and responsible use of these expensive biotherapies.

The LISA-TRACKER kits, manufactured by Theradiag, enable simultaneous or individual measurement of TNFα, anti-TNFα and anti-drug antibodies (ADAb). The simple ELISA technique using serum samples gives automated results within 4 hours.

Monitoring the combination of these three parameters over time indicates the patient’s reaction to treatment; whether non-responsive, declining or positive. This information allows clinicians to anticipate, optimize, and better manage the patient’s treatment. Drug administration can be adjusted to try to improve effectiveness, or when patient response is good, reduced, to prevent over dosage side effects and decrease costs. Use of such tests can therefore improve patient care and save NHS expenses.

LISA-TRACKER kits are available for Infliximab, Adalimumab, Etanercept, Certolizumab, Golimumab. These therapeutic agents are widely prescribed to treat patients with various chronic inflammatory diseases. The biomarkers bind to TNFα blocking the action responsible for the inflammatory condition.

Also available are LISA-Tracker kits for Rituximab (anti-CD20) and Tocilizumab (anti-IL6r). Rituximab is used in Rhematoid Arthritis, non-Hodgkins lymphoma and Chronic lymphocytic leukaemia and Tocilizumab is used in Rheumatoid Arthritis.

Find out more about theranostic monitoring by clicking on the ‘request information’ tab below.

Request Info


Company website

Alpha Laboratories Ltd
profile photo

Sonia Nicholas
Clinical Diagnostics Editor